0
Startups & Venture·July 15, 2026·1 min read

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Share

A $2B pre-launch valuation for an AI drug discovery spinout from an OpenAI researcher says more about capital’s appetite for model-native biotech than about de-risked science. If you’re operating in life sciences, assume talent and capital will keep leaking toward AI-first platforms and plan partnerships and hiring accordingly.

Startups & Venture

InstaLILY, which develops AI agents to automate sales, operations, and service workflows, raised a $60M Series B led by Energize Capital

Agentic AI is moving from experiments to funded line-of-business automation — $60M into InstaLILY for sales, ops, and service ‘teammates’ is a bet that domain-specific workflows, not generic copilots, will own the budget. If you run a revenue or CX org, you now have to decide whether to buy vertical agents like this or let internal teams build on general-purpose stacks.

Startups & Venture

A look at Founders Fund-backed State Affairs, which raised $70M and uses AI trained on reporting by its 76 staffers to power a Bloomberg Terminal-like product

Training an in-house model on 76 reporters’ work to build a Bloomberg-style terminal is a bet that proprietary, structured reporting can be monetized as a data product, not just ad inventory. If you own a niche data exhaust — legal, industrial, local, scientific — this is your prompt to price it as an AI-native terminal, not another newsletter.